AcquisitionOther
Serapha Bio, Inc. acquired Boundless Bio, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
Serapha Bio, Inc. -> Boundless Bio, Inc. · $230 million
To combine and advance Serapha's in vivo base editing for Alpha-1 Antitrypsin Deficiency.
Open source record (SEC) ↗